Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age
Recruiting
This study is a Phase 3, randomized, modified double-blind study which aims to document the safety profile of the PCV21 vaccine (investigational pneumococcal vaccine) compared to a licensed 20-valent pneumococcal conjugate vaccine in infants aged from approximately 2 months (42 to 89 days). The study duration per participant will be up to approximately 19 months. The study vaccines (either PCV21 or 20vPCV) will be administered at approximately 2, 4, 6 and 12 to 15 months of age. Routine pediatr... Read More
Gender:
ALL
Ages:
Between 42 days and 89 days
Trial Updated:
08/21/2025
Locations: iResearch Savannah - CenExel - PPDS- Site Number : 8400057, Savannah, Georgia
Conditions: Pneumococcal Immunization
HPV Vaccine Reduced Dose
Recruiting
This study aims to answer the question: does 1-dose HPV vaccination generate the same immune responses compared to 2- or 3-dose HPV vaccination? This will be done by studying the immune response in blood, lymph nodes, and bone marrow. Human papillomaviruses (HPV) cause cancers (cervical, anal, oropharyngeal, vulvar, vaginal, and penile), and the current HPV vaccine is highly effective at preventing disease by HPV types that cause 90% of cancer cases. While this vaccine generates high levels of... Read More
Gender:
ALL
Ages:
Between 18 years and 45 years
Trial Updated:
08/19/2025
Locations: Hope Clinic of the Emory Vaccine Center, Decatur, Georgia
Conditions: HPV
TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer
Recruiting
This phase Ib trial tests the safety, side effects and best dose of tumor membrane vesicle (TMV) vaccine therapy alone and in combination with pembrolizumab and evaluates how well it works in treating patients with head and neck squamous cell cancer that has come back after a period of improvement (recurrent) or that has spread from where it first started (primary site) to other places in the body (metastatic). Vaccines made from a person's tumor cells, such as TMV vaccines, may help the body bu... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/18/2025
Locations: Emory University Hospital Midtown, Atlanta, Georgia +1 locations
Conditions: Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC V8, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma, Metastatic Laryngeal Squamous Cell Carcinoma, Metastatic Nasopharyngeal Squamous Cell Carcinoma, Metastatic Oral Cavity Squamous Cell Carcinoma, Metastatic Oropharyngeal Squamous Cell Carcinoma, Metastatic Sinonasal Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Nasopharyngeal Squamous Cell Carcinoma, Recurrent Oral Cavity Squamous Cell Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma, Recurrent Sinonasal Squamous Cell Carcinoma, Squamous Cell Carcinoma of Unknown Primary, Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC V8, Stage IV Hypopharyngeal Carcinoma AJCC V8, Stage IV Laryngeal Cancer AJCC V8, Stage IV Lip and Oral Cavity Cancer AJCC V8, Stage IV Nasopharyngeal Carcinoma AJCC V8, Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC V8, Stage IV Sinonasal Cancer AJCC V8
Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS
Active Not Recruiting
The purpose of this study is to collect long-term safety, tolerability, effectiveness and health outcomes data in eligible subjects who have participated in a Novartis ofatumumab clinical MS study. Vaccination sub-study The purpose of this research sub-study is to find out the effects of ofatumumab on the development of antibody responses to selected vaccines and keyhole limpet hemocyanin (KLH) neo-antigen in subjects with relapsing multiple sclerosis (RMS). COVID-19 sub-study: The purpose of... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
08/14/2025
Locations: Velocity Clinical Research, Savannah, Georgia +1 locations
Conditions: Relapsing Multiple Sclerosis
A Study to Evaluate the Safety and Immunogenicity of RSVpreF Coadministered With Herpes Zoster Vaccine in Adults
Active Not Recruiting
This purpose of this phase 3 multicenter, parallel-group, open-label study is to learn about the safety, tolerability, and immunogenicity of RSVpreF and HZ/su vaccine when given together in adults 50 years of age and older.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
08/13/2025
Locations: Centricity Research Columbus Georgia Multispecialty, Columbus, Georgia +1 locations
Conditions: Respiratory Syncytial Virus (RSV)
A Study to Learn About Flu and COVID-19 Vaccine Responses in Healthy People
Completed
This study is to learn about flu and COVID vaccines, either alone or when mixed together. Healthy people aged 18 or older can join. Participants will get one shot in each arm, either a flu or COVID vaccine, alone or mixed. The study lasts about 6 months, and participants need to visit the research site at least 3 times.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: Clinical Research Atlanta, Stockbridge, Georgia
Conditions: Influenza,Human, COVID-19
CDC-9 Inactivated Rotavirus Vaccine (IRV) Microneedle Patch (MNP) in Healthy Adults
Recruiting
This is a study of CDC-9 inactivated rotavirus vaccine (IRV) microneedle patch (MNP) for intradermal administration in healthy adults aged 18 to 45 years at two dose levels in a 3-dose series. The purpose is to determine if it is safe and if the recipient's immune system responds to the vaccine.
Gender:
ALL
Ages:
Between 18 years and 45 years
Trial Updated:
08/08/2025
Locations: Emory Children's Center - Vaccine Research Clinic, Atlanta, Georgia
Conditions: Rotavirus Infections
CDC-9 Inactivated Rotavirus Vaccine (IRV) Intramuscular (IM) Phase 1 Clinical Trial in Healthy Adults
Active Not Recruiting
This is a study of CDC-9 inactivated rotavirus vaccine (IRV) for intramuscular administration (IM) in healthy adults aged 18 to 45 years at two dose levels in a 3-dose series. The purpose is to determine if it is safe and if the recipient's immune system responds to the vaccine.
Gender:
ALL
Ages:
Between 18 years and 45 years
Trial Updated:
08/08/2025
Locations: Emory Children's Center - Vaccine Research Clinic, Atlanta, Georgia
Conditions: Rotavirus Infections
COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders
Terminated
This is a randomized, multi-site, adaptive, open-label clinical trial comparing the immune response to different additional doses of COVID-19 vaccine in participants with autoimmune disease requiring IS medications. All study participants will have negative serologic or suboptimal responses (defined as a Roche Elecsys® Anti-SARS-CoV-2 S result ≤200 U/mL) or a low immune response (defined as a Roche Elecsys® Anti-SARS-CoV-2 S result \>200 U/ml and ≤2500 U/mL) to their previous doses of COVID-19 v... Read More
Gender:
ALL
Ages:
2 years and above
Trial Updated:
08/04/2025
Locations: The Emory Clinic: Division of Rheumatology, Atlanta, Georgia
Conditions: Systemic Lupus Erythematosus (SLE), Pemphigus Vulgaris, Systemic Sclerosis (SSc), Pediatric SLE, Pediatric-Onset Multiple Sclerosis (POMS), Rheumatoid Arthritis (RA), Multiple Sclerosis (MS), Juvenile Idiopathic Arthritis (JIA), Juvenile Dermatomyositis (JDM)
COVID19 SARS Vaccinations: Systemic Allergic Reactions to SARS-CoV-2 Vaccinations
Completed
Background: Allergic reactions have been reported to occur after vaccination with both the Pfizer-BioNTech COVID-19 Vaccine and Moderna COVID-19 Vaccine. Allergic reactions range from mild to severe and include life- threatening anaphylactic reactions, although no deaths have been reported with either vaccine. This study is designed with two principal aims: * To estimate the proportions of systemic allergic reactions to the Pfizer-BioNTech COVID-19 Vaccine and the Moderna COVID-19 Vaccine in a... Read More
Gender:
ALL
Ages:
5 years and above
Trial Updated:
07/25/2025
Locations: Emory University School of Medicine, Emory Healthcare: Emory Clinic Allergy and Immunology, Atlanta, Georgia
Conditions: SARS-CoV Infection, COVID-19, Allergic Reaction, Mast Cell Disorder
A Safety Trial to Test MVA-BN(R)-Filo and Ad26.ZEBOV Vaccines in Healthy Volunteers
Completed
This is a Phase 1, double-blind, randomized trial to evaluate the safety and immunogenicity of two heterologous and two homologous prime-boost regimens using MVA-BN(R)-Filo and Ad26.ZEBOV administered in different sequences at Days 1 and 29 in healthy adult subjects aged 18 - 45 years. The study will evaluate the 'omics (transcriptomics, proteomics, lipidomics, metabolomics), antibodies for immunogenicity, CMI, ADCC, and plasmablast responses to MVA-BN(R)-Filo and Ad26.ZEBOV vaccines. The primar... Read More
Gender:
ALL
Ages:
Between 18 years and 45 years
Trial Updated:
07/24/2025
Locations: Emory University School of Medicine, Atlanta, Georgia
Conditions: Ebola Disease, Marburg Disease
VGX-3100 and Electroporation in Treating Patients With HIV-Positive High-Grade Anal Lesions
Completed
This phase II trial studies the use of human papillomavirus (HPV) deoxyribonucleic acid (DNA) plasmids therapeutic vaccine VGX-3100 (VGX-3100) and electroporation in treating patients with human immunodeficiency virus (HIV)-positive high-grade anal lesions. Vaccines made from DNA may help the body build an effective immune response to kill tumor cells. Electroporation helps pores in your body's cells take in the drug to strengthen your immune system's response. Giving VGX-3100 and electroporatio... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/15/2025
Locations: Grady Health System, Atlanta, Georgia
Conditions: Anal Intraepithelial Neoplasia, High Grade Squamous Intraepithelial Neoplasia, HIV Positivity, Human Papillomavirus-16 Positive, Human Papillomavirus-18 Positive